Floatz logo

Girentuximab

Clear Cell Renal Cell Carcinoma

Massachusetts General Hospitalmonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
73/ 100

Competitive context

115 Active assets in the Clear Cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
gw786034
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB
LENVATINIB
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB

View all 50 →

Same molecule, other indications

Girentuximab is also rated in:

kidney cancerDormant
BB
Indicative ·
70 / 100
View asset →
kidney cancerDormant
BB
Indicative ·
69 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →